E7777

Phase 3Small molecule

Eisai

E7777 is one of 80 small molecule programs targeting Lymphoma. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

LymphomaActive, not recruiting

Cutaneous T-Cell LymphomaActive, not recruiting

LymphomaPhase 3

Active, not recruiting

Cutaneous T-Cell LymphomaPhase 3

Active, not recruiting

Competition

Competitive Landscape

1774 competitors in Lymphoma

#DrugCompanyPhaseTrials

E7777

Eisai

Phase 3

1 2

Blenoxane

SSequus Pharmaceuticals

Preclinical

25 3

Oncaspar

SServier

Preclinical

15 4

Zofran

Novartis

Preclinical

2 5

Tafasitamab

Incyte

Preclinical

7 6

Emend

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Preclinical

1 7

Kenalog

BBausch Health Americas, Inc.

Preclinical

1 8

Nuvigil

NNuvo Research GmbH

Preclinical

1 9

Systemic Therapy

Bristol-Myers Squibb

Preclinical

1 10

PEG-Intron

Merck & Co.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 1/2Recruiting

Recurrent or Metastatic Solid Tumors

NCT05200559

Clinical

Trials by Indication[1]

Cutaneous T-cell lymphoma2 trials

Study of E7777 in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma and Cutaneous T-cell Lymphoma

Completed· Eisai logo

Eisai·Phase 2·NCT02676778·45 enrolled

A Trial of E7777 in Persistent and Recurrent Cutaneous T-Cell Lymphoma

Completed· Eisai logo

Eisai·Phase 3·NCT01871727·112 enrolled

Recurrent or Metastatic Solid Tumors1 trial

T-regulatory Cell Depletion with E7777 Combined with Pembrolizumab in Recurrent or Metastatic Solid Tumors

Recruiting·—·Phase 1/2·NCT05200559·70 enrolled

CAR-T1 trial

Ph I/II Study of E7777 Prior to CAR-T for R/R LBCL

Suspended·MMasonic Cancer Center, University of Minnesota·Phase 1/2·NCT04855253·30 enrolled

Lymphoma1 trial

A Phase 3 Trial of E7777 in Combination With CHOP Compared With CHOP Alone for the First-Line Treatment of Peripheral T-cell Lymphoma

Withdrawn· Eisai logo

Eisai·Phase 3·NCT01355783

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for E7777. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — E7777 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for E7777. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Eisai company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Eisai

E7777

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Trials by Indication[1]

Cutaneous T-cell lymphoma2 trials

Recurrent or Metastatic Solid Tumors1 trial

CAR-T1 trial

Lymphoma1 trial

References

Drug Info

Quick Facts

Related News